Structure Therapeutics Inc. (NASDAQ:GPCR) Position Boosted by Fmr LLC

Fmr LLC increased its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 6.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,128,444 shares of the company’s stock after purchasing an additional 383,635 shares during the quarter. Fmr LLC owned approximately 0.11% of Structure Therapeutics worth $268,977,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Sandia Investment Management LP purchased a new stake in Structure Therapeutics in the 2nd quarter worth approximately $39,000. Assetmark Inc. boosted its position in Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after purchasing an additional 719 shares during the last quarter. Quarry LP purchased a new position in Structure Therapeutics in the second quarter valued at about $79,000. Mirae Asset Global Investments Co. Ltd. increased its position in Structure Therapeutics by 60.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after purchasing an additional 1,420 shares during the last quarter. Finally, Dearborn Partners LLC purchased a new stake in shares of Structure Therapeutics during the 3rd quarter worth about $202,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on GPCR shares. JMP Securities dropped their price objective on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Morgan Stanley initiated coverage on shares of Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, September 23rd. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics currently has an average rating of “Buy” and an average price target of $86.80.

Structure Therapeutics Trading Down 1.8 %

Shares of Structure Therapeutics stock opened at $33.15 on Monday. The firm has a fifty day simple moving average of $38.21 and a 200-day simple moving average of $39.45. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -44.80 and a beta of -3.23. Structure Therapeutics Inc. has a 1-year low of $26.61 and a 1-year high of $66.38.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.